Lilly Cymbalta Halted By GMP Issues; “Approvable” Letter Issued Sept. 13
Executive Summary
Lilly plans to keep the fill-finish production of Cymbalta (duloxetine) in Indianapolis and resolve FDA's good manufacturing practices concerns rather than pursue an alternate manufacturing arrangement for the antidepressant, Lilly said after receiving an "approvable" letter Sept. 13
You may also be interested in...
UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004
UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004
UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004
UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004
Lilly Cymbalta Launched At Premium Price; Once-Daily Dose Encouraged
Lilly's antidepressant Cymbalta is priced at a 73% premium to Wyeth's Effexor XR